HER2 抑制劑市場規模、佔有率、成長分析（按療法、應用、最終用戶、地區）- 產業預測（2025 年至 2032 年）

HER2 Inhibitors Market Size, Share, and Growth Analysis, By Treatment (Monotherapy, Combination Therapy), By Application (Squamous Cell Carcinoma, Adenocarcinoma), By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年07月02日 | 出版商:

SkyQuest | 英文 195 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計 2023 年全球 HER2 抑制劑市場規模將達到 92 億美元，並從 2024 年的 101.4 億美元成長到 2032 年的 220.5 億美元，預測期內（2025-2032 年）的複合年成長率為 10.2%。

乳癌和胃癌（尤其是 HER2 陽性變異型）發生率的上升，推動了全球對 HER2 抑制劑的需求，而 HER2 抑制劑對於標靶癌症治療至關重要。這些惡性腫瘤的存活率較低，因此旨在改善患者預後的精準治療日益增多。免疫組織化學 (IHC) 和螢光原位雜合反應(FISH) 等診斷技術的進步提高了早期檢測率，進一步增強了 HER2 抑制劑的應用。同時，新型抗體藥物複合體(ADC) 和生物相似藥的推出降低了藥品成本，擴大了重要治療的可及性。美國FDA 和 EMA 的監管支持以及 HER2標靶治療藥物的快速核准途徑，加強了臨床開發，使 HER2 抑制劑成為腫瘤學產品組合的焦點，推動了市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益同比對比（2022-2024 年）

主要企業簡介

Genentech（USA）
Hoffmann-La Roche（Switzerland）
Pfizer Inc.（USA）
AstraZeneca（United Kingdom）
Novartis AG（Switzerland）
Amgen Inc.（USA）
Eli Lilly and Company（USA）
Biogen Inc.（USA）
Sanofi SA（France）
Symbio Pharmaceuticals（USA）
Puma Biotechnology（USA）
Ipca Laboratories（India）

結論和建議

簡介目錄

Product Code: SQMIG35I2392

Global HER2 Inhibitors Market size was valued at USD 9.2 billion in 2023 and is poised to grow from USD 10.14 billion in 2024 to USD 22.05 billion by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

The rising prevalence of breast and gastric cancers, particularly HER2-positive variants, is driving the global demand for HER2 inhibitors, crucial for targeted cancer therapies. These aggressive cancers exhibit lower survival rates, prompting an increase in precision treatments aimed at improving patient outcomes. Advancements in diagnostic technologies such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are enhancing early detection, further elevating the use of HER2 inhibitors. Concurrently, the introduction of new antibody-drug conjugates (ADCs) and biosimilars is reducing drug costs and expanding access to vital care. Regulatory support from the U.S. FDA and EMA, alongside expedited approval pathways for HER2-targeted therapies, is bolstering clinical development, positioning HER2 inhibitors as a focal point in oncology portfolios and driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HER2 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HER2 Inhibitors Market Segments Analysis

Global HER2 Inhibitors Market is segmented by Treatment, Application, End User and region. Based on Treatment, the market is segmented into Monotherapy and Combination Therapy. Based on Application, the market is segmented into Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer and Other Applications. Based on End User, the market is segmented into Hospitals, Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HER2 Inhibitors Market

The rising incidence of HER2-positive cancers, particularly in breast and gastric cancer cases, significantly drives the growth of the global HER2 inhibitors market. Enhanced education and awareness, alongside advancements in diagnostic capabilities, have led to improved early detection rates, resulting in a larger pool of patients requiring HER2-targeted therapies. This expanding patient demographic is not only increasing the market share for HER2 inhibitors globally but is also fueling the ongoing demand for improved and innovative HER2 inhibitor treatments within healthcare systems worldwide. Consequently, the need for advanced therapies continues to rise, further establishing the significance of this market segment.

Restraints in the Global HER2 Inhibitors Market

The Global HER2 Inhibitors market faces significant constraints primarily due to the high costs associated with these therapies. Although HER2 inhibitors offer substantial clinical benefits, their exorbitant prices severely limit access, especially in low- and middle-income countries. This financial burden affects healthcare systems and patients alike, creating a significant barrier to accessing these potentially life-saving treatments. Consequently, the high treatment costs hinder market growth and impede equitable access to advanced oncological therapies on a global scale. As a result, the potential for widespread adoption and improved patient outcomes remains significantly restricted.

Market Trends of the Global HER2 Inhibitors Market

The global HER2 inhibitors market is witnessing significant growth, propelled by advancements in targeted therapy and the rise of personalized medicine. Innovative HER2 inhibitors are being developed with enhanced specificity and efficacy, tailored specifically for HER2-positive cancers. This evolution not only aims to improve patient outcomes but also seeks to minimize adverse side effects associated with conventional treatments. The increasing prevalence of HER2-positive tumors, coupled with a growing emphasis on individualized treatment plans, is driving demand for these therapeutics. As a result, pharmaceutical companies are intensifying research and development efforts, further shaping the landscape of the HER2 inhibitors market for the foreseeable future.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis
Case Studies

Global HER2 Inhibitors Market Size by Treatment & CAGR (2025-2032)

Market Overview
Monotherapy
- Single-Agent HER2 Inhibitors
- Targeted HER2 Therapies
Combination Therapy
- HER2 Inhibitors Combined With Chemotherapy
- HER2 Inhibitors Combined With Targeted Therapies
- HER2 Inhibitors Combined With Hormonal Therapies

Global HER2 Inhibitors Market Size by Application & CAGR (2025-2032)

Market Overview
Squamous Cell Carcinoma
Adenocarcinoma
Large Cell Carcinoma
Breast Cancer
Other Applications

Global HER2 Inhibitors Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Other End Users

Global HER2 Inhibitors Market Size & CAGR (2025-2032)

North America (Treatment, Application, End User)
- US
- Canada
Europe (Treatment, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Genentech (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Symbio Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Puma Biotechnology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipca Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments